Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis

被引：9

作者：

Nie, Run-Cong ^{[1
]}

Duan, Shu-Qiang YuanJin-Ling ^{[1
,3
]}

Liang, Yao ^{[1
]}

Chen, Xiao-Jiang ^{[1
]}

Chen, Yong-Ming ^{[1
]}

Luo, Tian-Qi ^{[1
]}

Chen, Guo-Ming ^{[1
]}

Wang, Yun ^{[2
]}

Li, Yuan-Fang ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Dept Gastr Surg,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,Canc Ctr, Guangzhou, Peoples R China

[3] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Peoples R China

来源：

IMMUNOTHERAPY | 2020年 / 12卷 / 18期

关键词：

efficacy; immunotherapy; overall survival; PD-1; PD-L1; smoking; OPEN-LABEL; CANCER-IMMUNOTHERAPY; CHOICE CHEMOTHERAPY; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; DOCETAXEL; BLOCKADE; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.2217/imt-2020-0007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim:This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents.Materials & methods:We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients.Results: 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy.Conclusion:There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.

引用

页码：1313 / 1324

页数：12

共 50 条

[21] Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
Chen, Yueying
Han, Hedong
Cheng, Jing
Cheng, Qinpei
Zhu, Suhua
Zhan, Ping
Liu, Hongbing
Song, Yong
Lv, Tangfeng
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (08)
[22] Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.
Carretero-Gonzalez, Alberto
Otero, Irene
Lora, David
Carril-Ajuria, Lucia
Castellano, Daniel
de Velasco, Guillermo
ONCOIMMUNOLOGY, 2021, 10 (01):
[23] Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis
Liu, Xi
Guo, Chang-Ying
Tou, Fang-Fang
Wen, Xiao-Ming
Kuang, Yu-Kang
Zhu, Qian
Hu, Hao
INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 116 - 127
[24] The safety and efficacy of anti-PD-1/PD-L1 monoclonal antibodies for lung cancer brain metastasis: a systematic review and meta-analysis on brain metastasis
Delbari, Pouria
Ahmadvand, Muhammad Hussain
Mirjani, Mohammad Sina
Hajikarimloo, Bardia
Rad, Romina Hamidi
Kargar-Soleimanabad, Saeed
Edalat, Mehrshad
Bahri, Amirmohammad
Eftekhar, Mohammad Shahir
Mohammadzadeh, Ibrahim
Habibi, Mohammad Amin
NEUROSURGICAL REVIEW, 2025, 48 (01)
[25] Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
Wang, Bi-Cheng
Zhang, Zhan-Jie
Fu, Chen
Wang, Chang
MEDICINE, 2019, 98 (47)
[26] PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Gandini, Sara
Massi, Daniela
Mandala, Mario
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 88 - 98
[27] PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
Abdel-Rahman, Omar
IMMUNOTHERAPY, 2016, 8 (09) : 1081 - 1090
[28] The efficacy and safety of first-line anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A systematic review and meta-analysis of phase III randomized controlled trials
Duan, Xiaoyang
Du, Huazhen
Qi, Ran
Yuan, Meng
Shi, Jian
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 25 (05)
[29] Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
Al-Showbaki, Laith
Nadler, Michelle B.
Desnoyers, Alexandra
Almugbel, Fahad A.
Cescon, David W.
Amir, Eitan
JOURNAL OF CANCER, 2021, 12 (14): : 4372 - 4378
[30] Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
Liu, Kewei
Wang, Dongpo
Yao, Cong
Qiao, Min
Li, Qing
Ren, Weicong
Li, Shanshan
Gao, Mengqiu
Pang, Yu
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →